https://sciex.com/content/SCIEX/na/us/en


Getting a Clean Match in Forensic Toxicology using LC-MS/MS

Feb 6, 2017 | Blogs, Forensic | 0 comments

As a forensic scientist, what holds you back in the lab? It’s a question we often ask ourselves here at SCIEX, as product development depends on customer wants, needs, satisfaction, and ease of workflow. Ensuring evidence can withstand forensic scrutiny, for example, correlates with the integrity of testing procedures. Knowing this, how do you convince your staff to be confident in results, or convey technical data to a non-technical courtroom audience? If you have been left wondering how to get to the bottom of topics like these, check out the following toxicology toolkit. It’s a bundle of resources at your fingertips that includes a webinar led by Tania A. Saski Ph.D., Northwest Physician Laboratories, Bellevue, Using QTRAP® Technology to Provide Accurate Identification and Confirmation Beyond a Reasonable Doubt, and so much more.  Download Info Kit >

Tune in at your convenience to hear about her insights on four forensic cases with questionable results which were rectified using QTRAP® technology. When sample ratios are on the bubble and retention times vary, discover how LC-MS/MS can be a logical solution for difficult confirmations like opiate analysis. Gain higher confidence in your results and make it clear to everyone involved that you have a sample match.

In addition to the webinar, gain access to bundled application notes, a white paper, and in case you missed it, an e-seminar too. Want to get more insight into forensic applications? Visit, Border Security with Accuracy, Reliability, and Reproducibility.

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial